131 related articles for article (PubMed ID: 33450374)
21. Iron affects the sphere-forming ability of ovarian cancer cells in non-adherent culture conditions.
Battaglia AM; Sacco A; Vecchio E; Scicchitano S; Petriaggi L; Giorgio E; Bulotta S; Levi S; Faniello CM; Biamonte F; Costanzo F
Front Cell Dev Biol; 2023; 11():1272667. PubMed ID: 38033861
[No Abstract] [Full Text] [Related]
22. Sonosensitizer-Functionalized Graphene Nanoribbons for Adhesion Blocking and Sonodynamic Ablation of Ovarian Cancer Spheroids.
Lee HR; Kim DW; Jones VO; Choi Y; Ferry VE; Geller MA; Azarin SM
Adv Healthc Mater; 2021 Jul; 10(13):e2001368. PubMed ID: 34050609
[TBL] [Abstract][Full Text] [Related]
23. AMPK-Independent LKB1 Activity Is Required for Efficient Epithelial Ovarian Cancer Metastasis.
Buensuceso A; Ramos-Valdes Y; DiMattia GE; Shepherd TG
Mol Cancer Res; 2020 Mar; 18(3):488-500. PubMed ID: 31744879
[TBL] [Abstract][Full Text] [Related]
24. Multicellular detachment generates metastatic spheroids during intra-abdominal dissemination in epithelial ovarian cancer.
Al Habyan S; Kalos C; Szymborski J; McCaffrey L
Oncogene; 2018 Sep; 37(37):5127-5135. PubMed ID: 29789717
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of Ovarian Cancer Cell Spheroid Formation by Synthetic Peptides Derived from Nectin-4.
Boylan KLM; Manion RD; Shah H; Skubitz KM; Skubitz APN
Int J Mol Sci; 2020 Jun; 21(13):. PubMed ID: 32629816
[TBL] [Abstract][Full Text] [Related]
26. Ferritin heavy chain is a negative regulator of ovarian cancer stem cell expansion and epithelial to mesenchymal transition.
Lobello N; Biamonte F; Pisanu ME; Faniello MC; Jakopin Ž; Chiarella E; Giovannone ED; Mancini R; Ciliberto G; Cuda G; Costanzo F
Oncotarget; 2016 Sep; 7(38):62019-62033. PubMed ID: 27566559
[TBL] [Abstract][Full Text] [Related]
27. Autophagy Induction Results in Enhanced Anoikis Resistance in Models of Peritoneal Disease.
Chen JL; David J; Cook-Spaeth D; Casey S; Cohen D; Selvendiran K; Bekaii-Saab T; Hays JL
Mol Cancer Res; 2017 Jan; 15(1):26-34. PubMed ID: 27807188
[TBL] [Abstract][Full Text] [Related]
28. Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapy.
Sheta R; Bachvarova M; Plante M; Renaud MC; Sebastianelli A; Gregoire J; Navarro JM; Perez RB; Masson JY; Bachvarov D
J Transl Med; 2020 Nov; 18(1):439. PubMed ID: 33213473
[TBL] [Abstract][Full Text] [Related]
29. The iron chelator desferrioxamine synergizes with chemotherapy for cancer treatment.
Wang L; Li X; Mu Y; Lu C; Tang S; Lu K; Qiu X; Wei A; Cheng Y; Wei W
J Trace Elem Med Biol; 2019 Dec; 56():131-138. PubMed ID: 31466045
[TBL] [Abstract][Full Text] [Related]
30. FAK-ERK activation in cell/matrix adhesion induced by the loss of apolipoprotein E stimulates the malignant progression of ovarian cancer.
Lai H; Zhao X; Qin Y; Ding Y; Chen R; Li G; Labrie M; Ding Z; Zhou J; Hu J; Ma D; Fang Y; Gao Q
J Exp Clin Cancer Res; 2018 Feb; 37(1):32. PubMed ID: 29458390
[TBL] [Abstract][Full Text] [Related]
31. Preclinical evaluation of olaparib and metformin combination in BRCA1 wildtype ovarian cancer.
Hijaz M; Chhina J; Mert I; Taylor M; Dar S; Al-Wahab Z; Ali-Fehmi R; Buekers T; Munkarah AR; Rattan R
Gynecol Oncol; 2016 Aug; 142(2):323-31. PubMed ID: 27282964
[TBL] [Abstract][Full Text] [Related]
32. Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial.
Konstantinopoulos PA; Barry WT; Birrer M; Westin SN; Cadoo KA; Shapiro GI; Mayer EL; O'Cearbhaill RE; Coleman RL; Kochupurakkal B; Whalen C; Curtis J; Farooq S; Luo W; Eismann J; Buss MK; Aghajanian C; Mills GB; Palakurthi S; Kirschmeier P; Liu J; Cantley LC; Kaufmann SH; Swisher EM; D'Andrea AD; Winer E; Wulf GM; Matulonis UA
Lancet Oncol; 2019 Apr; 20(4):570-580. PubMed ID: 30880072
[TBL] [Abstract][Full Text] [Related]
33. TGF-β-regulated different iron metabolism processes in the development and cisplatin resistance of ovarian cancer.
Wu J; Liao Q; Zhang LI; Wu S; Liu Z
Oncol Res; 2023; 32(2):373-391. PubMed ID: 38186569
[TBL] [Abstract][Full Text] [Related]
34. Formation of stable small cell number three-dimensional ovarian cancer spheroids using hanging drop arrays for preclinical drug sensitivity assays.
Raghavan S; Ward MR; Rowley KR; Wold RM; Takayama S; Buckanovich RJ; Mehta G
Gynecol Oncol; 2015 Jul; 138(1):181-9. PubMed ID: 25913133
[TBL] [Abstract][Full Text] [Related]
35. Laminin-1-derived scrambled peptide AG73T disaggregates laminin-1-induced ovarian cancer cell spheroids and improves the efficacy of cisplatin.
Yoshida Y; Kurokawa T; Nishikawa Y; Orisa M; Kleinman HK; Kotsuji F
Int J Oncol; 2008 Mar; 32(3):673-81. PubMed ID: 18292945
[TBL] [Abstract][Full Text] [Related]
36. Inhibiting ULK1 kinase decreases autophagy and cell viability in high-grade serous ovarian cancer spheroids.
Singha B; Laski J; Ramos Valdés Y; Liu E; DiMattia GE; Shepherd TG
Am J Cancer Res; 2020; 10(5):1384-1399. PubMed ID: 32509386
[TBL] [Abstract][Full Text] [Related]
37. Down-regulation of PADI2 prevents proliferation and epithelial-mesenchymal transition in ovarian cancer through inhibiting JAK2/STAT3 pathway in vitro and in vivo, alone or in combination with Olaparib.
Liu L; Zhang Z; Zhang G; Wang T; Ma Y; Guo W
J Transl Med; 2020 Sep; 18(1):357. PubMed ID: 32951601
[TBL] [Abstract][Full Text] [Related]
38. Extracellular matrix mediates moruloid-blastuloid morphodynamics in malignant ovarian spheroids.
Langthasa J; Sarkar P; Narayanan S; Bhagat R; Vadaparty A; Bhat R
Life Sci Alliance; 2021 Oct; 4(10):. PubMed ID: 34376568
[TBL] [Abstract][Full Text] [Related]
39. Induction of anoikis and suppression of human ovarian tumor growth in vivo by down-regulation of Bcl-X(L).
Frankel A; Rosen K; Filmus J; Kerbel RS
Cancer Res; 2001 Jun; 61(12):4837-41. PubMed ID: 11406560
[TBL] [Abstract][Full Text] [Related]
40. Chromosomal Instability and mTORC1 Activation through PTEN Loss Contribute to Proteotoxic Stress in Ovarian Carcinoma.
Chui MH; Doodnauth SA; Erdmann N; Tiedemann RE; Sircoulomb F; Drapkin R; Shaw P; Rottapel R
Cancer Res; 2019 Nov; 79(21):5536-5549. PubMed ID: 31530568
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
